| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000006310 |
| Receipt No. | R000007461 |
| Scientific Title | Phase II study of early start of chemotherapy after excision of the primary colorectal cancer. (FUTURE 1102-Pearl star 02) |
| Date of disclosure of the study information | 2011/09/20 |
| Last modified on | 2019/05/23 (Ver. 4) |
| Basic information | ||
| Public title | Phase II study of early start of chemotherapy after excision of the primary colorectal cancer. (FUTURE 1102-Pearl star 02) | |
| Acronym | Phase II study of early start of chemotherapy after excision of the primary colorectal cancer. (FUTURE 1102-Pearl star 02) | |
| Scientific Title | Phase II study of early start of chemotherapy after excision of the primary colorectal cancer. (FUTURE 1102-Pearl star 02) | |
| Scientific Title:Acronym | Phase II study of early start of chemotherapy after excision of the primary colorectal cancer. (FUTURE 1102-Pearl star 02) | |
| Region |
|
|
| Condition | ||
| Condition | Colorectal Cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the efficacy of the early start of chemotherapy after excision of the primary colorectal cancer. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase II |
| Assessment | |
| Primary outcomes | Efficacy |
| Key secondary outcomes | Response rate
Time to treatment failure Overall survival Progression free survival Safety |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Oxaliplatin 130mg/m2 i.v. (day1)
Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine2,000mg/m2,p.o.(day1-14) to be repeated every 3 weeks |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1.Histologically confirmed colorectal cancer
2.Unresectable synchronous liver metastases 3.Resection of primary colorectal cancer 4.No prior chemotherapy and radiotherapy for colorectal cancer 5.Performance Status: 0-1 (ECOG criteria) 6.Age: 20 years to 75 years 7.Vital organ functions are preserved within 7 days prior to entry WBC :>= 3,000 and =< 12,000/mm3 Neutrophil : >=1,500/mm3 Platelet : >= 100,000/mm3 T.bil.: <= 2.0 mg/dl AST,ALT : <=100IU/l(in case of hepatic metastatic patients are <= 200IU/l) Creatinin : <= 1.35mg/dl(female),1.80mg/dl(male) 8.Signed written informed consent |
|||
| Key exclusion criteria | 1.Prior severe drug allergy
2.Cavity fluid which needs drainage 3.Presence of active infection 4.Symptomatic brain metastases 5.Multiple malignancy within 5 years disease free interval 6.Uncontrolled hypertension 7.Uncontrolled diabetes 8.Peripheral nerve disorder 9.Severe pulmonary disease 10.Significant electrocardiographic abnormality 11.Treatment with anti-platelet drug 12.Chronic systemic treatment of corticosteroid 13.Nursing or pregnant females, or females or males with female partners who are planning to pregnancy 14.Inadequate for study enrollment by the physician |
|||
| Target sample size | 18 | |||
| Research contact person | |||||||
| Last name of lead principal investigator |
|
||||||
| Organization | Fukuoka University School of Medicine | ||||||
| Division name | Department of Gastroenterological Surgery | ||||||
| Zip code | 814-0180 | ||||||
| Address | 7-45-1,Nanakuma,Johnan-ku,Fukuoka ,814-0180,Japan | ||||||
| TEL | 0928011011 | ||||||
| yy4160@yahoo.co.jp | |||||||
| Public contact | |||||||
| 1st name of contact person |
|
||||||
| Organization | Fukuoka University School of Medicine | ||||||
| Division name | Gastroenterological Surgery | ||||||
| Zip code | 814-0180 | ||||||
| Address | 7-45-1,Nanakuma,Johnan-ku,Fukuoka ,814-0180,Japan | ||||||
| TEL | 0928011011 | ||||||
| Homepage URL | |||||||
| yy4160@yahoo.co.jp | |||||||
| Sponsor | |
| Institute | Fukuoka Tumor Research(FUTURE) |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Fukuoka Univesity |
| Address | 7-45-1,Nanakuma |
| Tel | 0928011011 |
| yy4160@yahoo.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 福岡大学医学部消化器外科学 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | https://www.ncbi.nlm.nih.gov/pubmed/29863132 |
| Publication of results | Published |
| Result | |||||||
| URL related to results and publications | https://www.ncbi.nlm.nih.gov/pubmed/29863132 | ||||||
| Number of participants that the trial has enrolled | 18 | ||||||
| Results | https://www.ncbi.nlm.nih.gov/pubmed/29863132 |
||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results | |||||||
| Baseline Characteristics | Same as above |
||||||
| Participant flow | Same as above |
||||||
| Adverse events | Same as above |
||||||
| Outcome measures | Same as above |
||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007461 |